While the combination of gemcitabine and the targeted epidermal growth factor receptor (EGFR) inhibitor erlotinib showed a statistically significant improvement in medial overall survival (OS) compared to gemcitabine alone9, the improvement in median OS was less than two weeks and patients had considerable skin toxicity. This evidence concerns the gene EGFR and neoplasm.